These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21504397)

  • 21. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention.
    Koester S; Glanz J; Barón A
    AIDS Behav; 2005 Mar; 9(1):27-39. PubMed ID: 15812611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hygiene and uncertainty in qualitative accounts of hepatitis C transmission among drug injectors in Serbia.
    Rhodes T; Zikic B; Prodanović A; Kuneski E; Bernays S
    Soc Sci Med; 2008 Mar; 66(6):1437-47. PubMed ID: 18201809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
    Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
    AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention and treatment of hepatitis C in illicit drug users].
    Sakoman S
    Acta Med Croatica; 2009 Dec; 63(5):437-42. PubMed ID: 20198904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999.
    Thorpe LE; Ouellet LJ; Levy JR; Williams IT; Monterroso ER
    J Infect Dis; 2000 Dec; 182(6):1588-94. PubMed ID: 11069228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C prevention and true harm reduction.
    Madden A; Cavalieri W
    Int J Drug Policy; 2007 Oct; 18(5):335-7. PubMed ID: 17854719
    [No Abstract]   [Full Text] [Related]  

  • 27. 'Affording' new approaches to couples who inject drugs: A novel fitpack design for hepatitis C prevention.
    Fraser S; Treloar C; Gendera S; Rance J
    Int J Drug Policy; 2017 Dec; 50():19-35. PubMed ID: 28982041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users.
    Robinson GM; Reynolds JN; Robinson BJ
    N Z Med J; 1995 Mar; 108(996):103-5. PubMed ID: 7715873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users.
    Kretzschmar M; Wiessing L
    AIDS; 2008 Aug; 22(13):1527-37. PubMed ID: 18670211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Staying safe from hepatitis C: engaging with multiple priorities.
    Harris M; Treloar C; Maher L
    Qual Health Res; 2012 Jan; 22(1):31-42. PubMed ID: 21873284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The missing mass of morality: a new fitpack design for hepatitis C prevention in sexual partnerships.
    Fraser S
    Int J Drug Policy; 2013 May; 24(3):212-9. PubMed ID: 23602226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
    Maher L; Chant K; Jalaludin B; Sargent P
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs.
    Davis M; Rhodes T; Martin A
    Soc Sci Med; 2004 Nov; 59(9):1807-18. PubMed ID: 15312916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
    Copeman M
    Med J Aust; 2003 Jul; 179(2):119; author reply 119. PubMed ID: 12864712
    [No Abstract]   [Full Text] [Related]  

  • 36. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors.
    Brewer DD; Hagan H; Sullivan DG; Muth SQ; Hough ES; Feuerborn NA; Gretch DR
    J Infect Dis; 2006 Sep; 194(6):764-72. PubMed ID: 16941342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of injection drug user (IDU) syringe sharing: the relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada.
    Shaw SY; Shah L; Jolly AM; Wylie JL
    Addiction; 2007 Oct; 102(10):1626-35. PubMed ID: 17854339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus. Epidemiology, transmission and prevention.
    van der Poel CL
    Curr Stud Hematol Blood Transfus; 1994; (61):137-63. PubMed ID: 7956327
    [No Abstract]   [Full Text] [Related]  

  • 39. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008.
    Iversen J; Wand H; Gonnermann A; Maher L;
    Int J Drug Policy; 2010 Nov; 21(6):471-6. PubMed ID: 20472417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing hepatitis C: what do positive injectors do?
    Carruthers SJ
    Drug Alcohol Rev; 2005 Mar; 24(2):193-8. PubMed ID: 16076589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.